Sales Drop for Cervical Cancer Vaccine Gardasil

The Wall Street Journal: Merck Buffeted by Analyst Report, by Avery Johnson:

Merck & Co.'s shares dropped 4.8% after an analyst report questioned whether sales of the cervical-cancer vaccine Gardasil have met Wall Street estimates for the second quarter.

UBS pharmaceuticals analyst Roopesh Patel cut his rating on the Whitehouse Station, N.J., drug maker, saying U.S. Gardasil sales may have fallen about $50 million short of expectations.